問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Cardiovascular Diseases

更新時間：2023-09-19

王俊力
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

3Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王俊力

List

14Cases

2007-03-01 - 2008-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2024-07-30 - 2028-09-30

Phase III

Active
EASi-HF Preserved – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) ≥40%

  • Condition/Disease

    heart failure

  • Test Drug

    cpasule

Participate Sites
10Sites

Recruiting10Sites

2024-02-27 - 2030-01-27

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting1Sites

Suspended15Sites

2025-09-30 - 2032-03-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2026-01-01 - 2031-09-18

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

2023-05-08 - 2027-07-02

Phase III

Active
HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation.

  • Condition/Disease

    heart failure

  • Test Drug

    injection

Participate Sites
5Sites

Not yet recruiting5Sites

2024-07-30 - 2028-09-30

Phase III

EASi-HF – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) ≥40%

  • Condition/Disease

    heart failure

  • Test Drug

    BI 690517empagliflozin

Participate Sites
10Sites

Not yet recruiting8Sites

Recruiting2Sites

2007-05-01 - 2008-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2018-11-19 - 2022-12-01

Phase III

An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

  • Condition/Disease

    Heart Failure With Preserved Ejection Fraction (HFpEF)

  • Test Drug

    dapagliflozin film-coated tablets

Participate Sites
15Sites

Recruiting13Sites

江晨恩
Taipei Veterans General Hospital

Division of Cardiovascular Diseases

2015-10-02 - 2019-03-31

Phase II

A Prospective, Double Blind, Randomized, Placebo-controlled Trial of Antroquinonol in Patients with Hypercholesterolemia and Hyperlipidemia

  • Condition/Disease

    Hypercholesterolemia and Hyperlipidemia

  • Test Drug

    Hocena®

Participate Sites
6Sites

Terminated6Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB